Literature DB >> 14716720

Family-based association tests for survival and times-to-onset analysis.

Christoph Lange1, Deborah Blacker, Nan M Laird.   

Abstract

In this paper, we discuss family-based association test (FBATs) relating genetic data to survival and time-to-onset data. We show how the standard logrank and Wilcoxon statistics can be used with family data to develop tests of association. We prove that the FBAT-logrank approach can be identical to the proportional hazard approach discussed in Mokliatchouk et al. (2000). Further, using simulation studies, we compare the power of the logrank, Wilcoxon and an approach developed for censored exponential data (Euro J Hum Gen 2001; 9:301-306). Based on the results of the simulation study, we suggest rules of thumb about which statistics to use in a given situation. An application of all three tests to an Alzheimer study illustrates the practical relevance of our discussion. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 14716720     DOI: 10.1002/sim.1707

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  21 in total

1.  Family-based association analysis of NAV2 gene with the risk and age at onset of Alzheimer's disease.

Authors:  Ke-Sheng Wang; Ying Liu; Chun Xu; Xuefeng Liu; Xingguang Luo
Journal:  J Neuroimmunol       Date:  2017-06-27       Impact factor: 3.478

2.  PBAT: tools for family-based association studies.

Authors:  Christoph Lange; Dawn DeMeo; Edwin K Silverman; Scott T Weiss; Nan M Laird
Journal:  Am J Hum Genet       Date:  2004-02       Impact factor: 11.025

Review 3.  Genome-wide association studies and the genetic dissection of complex traits.

Authors:  Paola Sebastiani; Nadia Timofeev; Daniel A Dworkis; Thomas T Perls; Martin H Steinberg
Journal:  Am J Hematol       Date:  2009-08       Impact factor: 10.047

4.  A doubly robust test for gene-environment interaction in family-based studies of affected offspring.

Authors:  Beatrijs Moerkerke; Stijn Vansteelandt; Christoph Lange
Journal:  Biostatistics       Date:  2010-02-12       Impact factor: 5.899

5.  Bayesian Cox Proportional Hazards Model in Survival Analysis of HACE1 Gene with Age at Onset of Alzheimer's Disease.

Authors:  Ke-Sheng Wang; Ying Liu; Shaoqing Gong; Chun Xu; Xin Xie; Liang Wang; Xingguang Luo
Journal:  Int J Clin Biostat Biom       Date:  2017-12-01

6.  Non-parametric Survival Analysis of EPG5 Gene with Age at Onset of Alzheimer's Disease.

Authors:  Ke-Sheng Wang; Xuefeng Liu; Changchun Xie; Ying Liu; Chun Xu
Journal:  J Mol Neurosci       Date:  2016-09-01       Impact factor: 3.444

7.  Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men.

Authors:  Yi-Hsiang Hsu; Tianhua Niu; Henry A Terwedow; Xin Xu; Yan Feng; Zhiping Li; Joseph D Brain; Cliff J Rosen; Nan Laird; Xiping Xu
Journal:  Hum Genet       Date:  2005-10-26       Impact factor: 4.132

8.  A comparison of popular TDT-generalizations for family-based association analysis.

Authors:  Julian Hecker; Nan Laird; Christoph Lange
Journal:  Genet Epidemiol       Date:  2019-01-04       Impact factor: 2.135

9.  An association between the PTGS2 rs5275 polymorphism and colorectal cancer risk in families with inherited non-syndromic predisposition.

Authors:  Jason Ross; Linda Lockett; Diana Brookes; Bruce Tabor; Konsta Duesing; Michael Buckley; Trevor Lockett; Peter Molloy; Finlay Macrae; Graeme Young; Ignacio Blanco; Gabriel Capella; Garry N Hannan
Journal:  Eur J Hum Genet       Date:  2013-03-27       Impact factor: 4.246

10.  On the analysis of genome-wide association studies in family-based designs: a universal, robust analysis approach and an application to four genome-wide association studies.

Authors:  Sungho Won; Jemma B Wilk; Rasika A Mathias; Christopher J O'Donnell; Edwin K Silverman; Kathleen Barnes; George T O'Connor; Scott T Weiss; Christoph Lange
Journal:  PLoS Genet       Date:  2009-11-26       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.